Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (21814)	11/2/2006 6:56:37 PM
From: Robohogs	Respond to of 52153

On ICOS options, nothing spectacular - 20 cent bids on most of the $35 strikes. I sold yesterday too - uggghh!

To: Biomaven who wrote (21814)	11/2/2006 7:25:53 PM
From: Gary Mohilner	Respond to of 52153

I know it's be awhile since I've mentioned IMGN to you. I suggest you take another look now, before things really start to happen. Next week their two pipeline drugs present at AACR/EORTC, Mitch Sayare won't discuss results until the presentation, but he did say that a Phase II was planned for C242-DM4 by mid year. He also announced that for now they had to stop taking patients into the N901-DM1 Trial because they need more N901. Two reasons, dosages are going higher than anticipated, and patients are remaining on the drug. While the delay's not positive, the reasons are, especially if you figure most the involved patients have relapsed or refractory SCLC. Drugs are only given on a repeated basis if patients are seeing benefits. SCLC is a very deadly cancer, any drug benefitting these patients should eventually be approved if they pursue it. It may be awhile before the stock sees new all time highs, but I've got to believe it will make new highs for the year before it ends. Gary